Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age

Next Previous
Trial Profile

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine quadrivalent-Seqirus (Primary) ; MF 59
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections; Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Vaccines; Seqirus

Most Recent Events

  • 24 May 2020 Russia was the planned location according to European Clinical Trials Database
  • 12 May 2020 Results published in the Pediatric Infectious Disease Journal
  • 30 Aug 2019 According to an Seqirus, CSL Media Release, new clinical data from this study were presented at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top